US 10287295
TGF-β inhibitors
granted A61PA61P1/04A61P1/16
Quick answer
US patent 10287295 (TGF-β inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61P, A61P1/04, A61P1/16, A61P11/00, A61P13/08